General description
Anthrax Edema Factor Antibody: Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF). PA binds to two related proteins on the cell surface; these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) and capillary morphogenesis protein 2 (CMG2), although it is still unclear which is physiologically relevant. Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease. The bound fragment binds both LF and EF; the resulting complex is then endocytosed which allows the translocation of LF and EF into the cytoplasm. EF is a calmodulin and Ca++-dependent adenylate cyclase responsible for the edema seen in the disease. It is thought to benefit the B. anthracis bacteria by inhibiting cells of the host immune system.
Immunogen
Anthrax Edema Factor antibody was raised against a synthetic peptide corresponding to 16 amino acids near the carboxy terminus of the Anthrax edema factor protein.The immunogen is located within the last 50 amino acids of Anthrax Edema Factor.
Application
Anthrax Edema Factor antibody can be used for the detection of Anthrax PA protein in ELISA. It will detect 10 ng of free peptide at 1 μg/mL.
Physical form
Supplied in PBS containing 0.02% sodium azide.
| biological source | rabbit |
| Quality Segment | 100 |
| conjugate | unconjugated |
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| clone | polyclonal |
| form | liquid |
| species reactivity | Bacillus anthracis |
| concentration | 1 mg/mL |
| technique(s) | ELISA: suitable |
| isotype | IgG |
| UniProt accession no. | P40136 |
| shipped in | wet ice |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
